77 The role of low dose busulfan (BU) (4MG/KG) with cyclophosphamide (CY) as a conditioning regimen for severe aplastic anaemia (SAA)  by Dulley, F.L. et al.
Poster  P resentat ions  - Sess ion  I 
77 
THE ROLE OF LOW DOSE BUSULFAN (BU) (4MG/RG) WITH 
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TransplmTtatio,~, State U~ive*si U ofCmnpinas, Campinas, &zoPaulo, 
Brazil; 2. U*zive'rsity of Sao Paulo, Sao Paulo, Sao Paulo, Brazil; 
3. Faculty of MediciTze -SJRPreto, SffRPreto, Sao Paulo, B~:azil. 
Bu is an agent currently used in BMT.Bu have minor toxicity to 
the lymphoid system and cause little immnnosuppression. Howev- 
er, successful allogeneic engraftment after the Tutschka regimen 
suggests that Bu can enhance the immunosupressive properties of 
Cy. Graft rejection has been a problem in SAA who were condi- 
tioned with Cy alone.Aiming to reduce graft rejection and to 
improve the immunosuppressive activity of Cy, we used Bn/Cy 
4mg/Kg and 200mg/Kg, respectively, as a conditioning in 8I pts 
with SAA.Pts were 3-53 years of age (mean, 24). The previous 
transfusions number was 1-276 (mean, 39), and 48% had therapy 
immunossupressive before transplant. MTX/CSA were used in 
order to prevent GVHD. 12/81 (15%) pts rejected their transplants 
in a mean time of 317 days (28-1001), 2 primarily (3%) and 10 
(12%) as a late rejection, aGVHD grades 2 or 3 occurred in 20/67 
(31%) pts and cGVHD in 24/61 (39%). The actuarial survival rate 
at 2850 days was 56% (CI 46-68%). In the nnivariate analysis age, 
previous treatment, number of previous transfusions, time of CSA 
use and aGVHD were statistically significant for survival. The OS 
for patients who received less and nmre than 15 transfusions was 
78% and 50%, respectively (P=0, 001); less and more than 50 
transfusions was 67% and 28%, respectively (P=0, 002). The 
cumulative incidence of rejection was 22% (CI 10-33%). In the 
univariate analysis number of previous transfusions and time of 
CSA were statistically significant for rejection. The cumulative 
incidence of rejection for patients who received less and more than 
50 transfusions was 15% and 43%, respectively (P=0, 06). The fol- 
lowing" risk factors were statistically significant for survival in the 
multivariate analysis: number of previous transfnsions, time of 
CSA, and aGVHD; for rejection: number of previous transfusions, 
and time of CSA.Low dose Bu/Cy showed to be effective and safe 
as conditioning regimen for SAA with acceptable rejection and 
survival rates. Moreover, higher number of transfusions showed to 
be associated with poor survival and more frequent rejections. 
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QUANTITATIVE DETECTION OF CHIMERISM AFTER ALLOGENEIC 
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For peripheral blood stem cell transplantation (PSCT), several 
methods for engraftment analysis, including detection f restric- 
tion fragment length polymorphisms and amplification of poly- 
morphic genetic loci, have been described previously. We report 
here a quantitative, non-isotopic method using short tandem 
repeat (STR) marker to facilitate the monitoring of engraftment. 
The DNA from the donors and the pre-transplant recipients were 
amplified with the AmpF1STR Profiler Plus kit that contained 9
STR markers. The fluorescent polymerase chain reaction prod- 
ucts were then fractionated on the ]d01yacrylamide gels in the ABI 
PRISM 377 DNA Sequencer and were analyzed by the GeneScan 
2.1 software. The best markers were selected as the informative 
alleles to distinguish donor from recipient. For quantitative analy- 
sis of engraftment, the chimeric samples were prepared by mixing 
pretransplant recipient and donor DNAs in different ratio to gen- 
erate a standard curve. After amplifying the post-transplant recipi- 
ent DNA, the extent of engraftment was determined by interpo- 
lating the percent peak area of the informative alleles according to 
the standard curve. This method was evaluated by the samples 
from 30 patients who received allogeneic PSCT during 1999 to 
2002. Four of them were informative for some degree of mixed 
chimerism indicating leukemic relapse. Of these 4 cases, 35%, 
6.5%, 15.5%, and 2.7% recipient DNA were first detected in the 
third, tenth, fourth, and fourth month after PSCT, respectively. 
These four mixed chimeric patients were soon treated with a rapid 
taper of immunosuppression. Three of them were then allowed a 
second PBST. In summary, this method provided an accurate, 
qlmntitative, and early assessment of mixed chimerism in post- 
transplant patients. Such information may be useful to guide 
implementation f additional treatment tocircumvent graft failure 
or relapse in the future. 
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STEM CELL TRANSPLANTATION IN AUSTRALIA AND NEW ZEALAND: 
AN UPDATE FROM THE AUSTRALASIAN BONE MARROW TRANS- 
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The ABMTRR has captured ata for an estimated 99.5% of trans- 
plants performed in the region from 1992-2001. In 2001, 1042 
transplants were performed, fewer than the peak of 1094 in 1998. 
This change is due to a reduction in staged, autologous transplants 
(mainly for breast cancer) and allografts for CML, despite an 
increase in unrelated onor and reduced-intensity allografts. For 
adult patients, the most common indications for single autografts 
(total 578) were NHL (42%), myeloma (35%) and Hodgldn lym- 
phorna (9%). There were 17 transplants performed for solid 
tumours (3 %) and 4 for autoinmmne disease, while 34 staged auto- 
grafts were done for myeloma (6), germ cell tammurs (6), breast can- 
cer (4) and others (18). Of 232 related onor allografts, AML (31%), 
CML (16%), ALL (11%) and NHL (10%) were the most conmaon 
indications. In i996, 97 patients were transplanted for breast cancer 
while in 2001 there were only 6. In 1999, there were 81 allografts 
for CML, 73 in 2000, but only 38 in 2001 coinciding with the initia- 
tion of trials with imafinih mesylate. For CML in Ist chronic phase, 
the numbers dropped from 63 in 1999 to 29 in 200I. Outcome data 
were available with a minimmn of 12 nmnths follow-up. For allo- 
grafts, the major cause of death in the first and second year was 
relapse (26%, 68%) with GVHD responsible for 15% and 5% 
respectively. For antografts disease-related deaths were 78% and 
86% in the first and second years. Of I673 adult recipients of related 
donor allografts, the estimated probability of survival at 9 years was 
42% and was 32% for 406 VUDS. We conclude that the ABMTRR 
is a valuable resource in identifying trends in transplantation. 
~ 2001 Australia 2001 New Zealand 
Total u ansplants ] 937 105 
Male;Female 582:355 61:44 
%male 02.1 58.1 
Number ol autografts 611 67 
AIIo related 234 29 
92 9 Allo unrelated 
ist tran~plant~ (allo&auto) 871 104 
2nd or 3rd transplants 66 l 
~taged autograt~s 57 3 
mismatched al/ografts 24 4 
age range tyr/ .3 75 1 64 
Aged 0-15 yr 109 22 
Aged 16-49 yr 391 45 
Aged 50+ yr 437 38 
% aged 50+ yz 46 6 362 
Number of contfibt,ting centres 3I 6 
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EFFECT OF ALLOGENEIC STEM CELL TRANSPLANTATION ON BONE 
MARROW (BM) ANGIOGENESIS IN CHRONIC MYELOGENOUS LEUKEMIA 
Kumar, S.; Litzow, M.R.; R_ajkumar, S. 3/layo Cli~zic, Rochester, MN. 
Aim: Angiogenesis or new vessel formation is integral to the 
biology of many malignancies. Increased BM angiogenesis has 
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